MedCity News January 8, 2025
Novo Nordisk and Valo Health have collaborated on the development of cardiovascular disease drugs since 2023. Expanding the alliance to cardiometabolic diseases nearly doubles the number of programs covered under the agreement.
Novo Nordisk’s collaboration with artificial intelligence startup Valo Health has focused on developing new drugs for cardiovascular disease. The pharmaceutical giant likes what it’s seen so far, and it’s now committing $190 million to expand the alliance to more cardiometabolic disorders, including obesity and type 2 diabetes.
The sum announced Wednesday encompasses an upfront payment, equity investment, and a potential near-term payment for a milestone that was not disclosed. The initial agreement inked in 2023 spanned up to 11 cardiovascular disease programs. Lexington, Massachusetts-based Valo received $60 million...
Today's Sponsors
Today's Sponsor